Eidos Therapeutics Inc

BridgeBio is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients. The BridgeBio approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of early stage science into medicines that treat disease at its source.

WILMINGTON, Del., Nov. 9, 2020 /PRNewswire/ -- Rigrodsky & Long, P.A. announces that it is investigating Eidos Therapeutics, Inc. ("Eidos") (NASDAQ GS: EIDX) regarding possible breaches of fiduciary duties and other violations of law related to Eidos' agreement to be acquired by BridgeBio...

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigation of Eidos Therapeutics, Inc. Buyout

NEW YORK, Oct. 31, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Eidos Therapeutics, Inc. (NASDAQ: EIDX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to...

ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - EIDX, RESI, PE, ARA

SAN FRANCISCO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the third quarter ended September 30, 2020 and provided an update on the company's operations.

Eidos Therapeutics Reports Third Quarter 2020 Financial Results and Business Update

NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Eidos Therapeutics, Inc. ("Eidos" or the "Company") (EIDX) relating...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Eidos Therapeutics, Inc. -EIDX

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Eidos Therapeutics, Inc. (NasdaqGS: EIDX) to BridgeBio Pharma, Inc. (NasdaqGS: BBIO). Under the terms of the proposed transaction, shareholders of Eidos will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash for each share of Eidos that they own. KSF is seeking to determine whether this co

EIDOS THERAPEUTICS INVESTOR ALERT BY The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Eidos Therapeutics, Inc. - EIDX

NEW YORK--(BUSINESS WIRE)--Labaton Sucharow, a nationally ranked shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against clinical-stage biotech company Eidos Therapeutics. (NASDAQ: EIDX). If you currently own shares of Eidos and want to receive additional information and protect your investments free of charge, please contact David J. Schwartz using the toll free number (800) 321-0476 or via email at dschwartz@labaton.com. About the

EIDX INVESTIGATION – Shareholder Rights Firm Labaton Sucharow is Investigating Eidos Therapeutics (NASDAQ: EIDX) for Potential Securities Violations and Breach of Fiduciary Duty

NEW YORK, Oct. 5, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Eidos Therapeutics, Inc. ("EIDX" or the "Company") (NASDAQ: EIDX) in connection with the proposed interested-party acquisition...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Eidos Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Eidos Therapeutics, Inc. (NASDAQ: EIDX) to BridgeBio Pharma, Inc. is fair to Eidos shareholders. On behalf of Eidos shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. If you are an Eidos shareholder and would like to discuss your legal rights an

Eidos Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Eidos Therapeutics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – EIDX

BridgeBio Pharma Inc

BridgeBio announced plans to fully acquire the biotech.

Why Eidos Therapeutics Stock Is Skyrocketing Today

New York, New York--(Newsfile Corp. - October 5, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders.newsfilecorp.com/files/7091/65213_5134e5c474e31b01_001full.jpgTo: All Persons or Entitie

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of BridgeBio Pharma, Inc. with Eidos Therapeutics, Inc. is Fair to BBIO Shareholders

BridgeBio Pharma Inc (NASDAQ: BBIO) said on Monday that it will increase its stake in Eidos Therapeutics Inc (NASDAQ: EIDX) by 36.3% in a cash deal that is valued at £134.95 million (aggregate maximum). At £30.54 per share, BridgeBio Pharma is currently 20% up year to date in the stock market after recovering from a low of £12.42 per share in March.

BridgeBio Pharma to increase its stake in Eidos Therapeutics by 36.3%

SAN DIEGO, Oct. 5, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Eidos Therapeutics, Inc. ("Eidos" or the "Company") (NASDAQ: EIDX) breached their fiduciary duties in connection with the proposed sale...

(EIDX) Alert: Johnson Fistel Investigates Proposed Sale of Eidos Therapeutics; Are Shareholders Getting a Fair Deal?

BridgeBio Pharma Inc. BBIO, announced Monday an agreement to buy Eidos Therapeutics Inc. EIDX, -0.30% in a deal that values Eidos at about $2.83 billion. Eidos's stock is currently halted for news, and BridgeBio shares are still untraded.

BridgeBio to buy Eidos Therapeutics in a cash and stock deal valuing Eidos at $2.8 billion

BridgeBio to Acquire All Outstanding Shares of E idos it Does Not Already Own

BridgeBio Pharma and Eidos Therapeutics Announce Merger Agreement

SAN FRANCISCO, Aug.  07, 2020  (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), today announced that it has added two new independent directors to its board who bring deep commercial and strategic experience to the company: Suzanne Sawochka Hooper, the former executive vice president and general counsel of Jazz Pharmaceuticals, and Duke Rohlen, the CEO and managing partner of Ajax Health.

Eidos Therapeutics Appoints Industry Leaders With Significant Development and Commercial Expertise to Board of Directors

SAN FRANCISCO, Aug.  06, 2020  (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX),  today reported its financial results for the second quarter ended June 30, 2020 and provided an update on the company’s operations.

Eidos Therapeutics Reports Second Quarter 2020 Financial Results and Business Update

Eidos Therapeutics (EIDX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Eidos Therapeutics (EIDX) Looks Good: Stock Adds 6.4% in Session

SAN FRANCISCO, May  08, 2020  (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX),  today reported its financial results for the first quarter ended March 31, 2020 and provided an update on the company’s operations.

Eidos Therapeutics Reports First Quarter 2020 Financial Results and Business Update

Axsome Therapeutics

Chemocentryx

DexCom

Enphase Energy

According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned stocks have outperformed the S&P 500 Index over the past 12 months as of March 31.

5 Guru Stocks That Beat the Market

Eidos Therapeutics (EIDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Eidos Therapeutics (EIDX) Stock Might be a Great Pick

ArQule

Arrowhead Pharmaceuticals

Guardant Health Inc

Kodiak Sciences Inc

Medpace Holdings

NeoGenomics

Nevro

Tenet Healthcare

Zoetis

Helping people stricken with illness can be richly rewarding in more ways than one.

These Were the 10 Best Healthcare Stocks of 2019

Akcea Therapeutics

AMAG Pharmaceuticals

Cronos Group

Heron Therapeutics

Ligand Pharmaceuticals

Paratek Pharma

PolarityTE Inc

Viking Therapeutics

Intrexon

ZIOPHARM Oncology

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

12 Biotech Stocks Primed For A Short Squeeze

Watch Out, Pfizer: This $2 Billion Biotech Is Coming for You

Eidos Therapeutics, Inc. (EIDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Eidos Therapeutics, Inc. (EIDX) Moves to Buy: Rationale Behind the Upgrade

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation

CORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

News for Eidos Therapeutics Inc Stock (EIDX)